Cannabix Technologies Adds Professor Dr. (h.c.) Marilyn A. Huestis as Scientific Advisor
April 20, 2016
Vancouver, British Columbia, April 20, 2016 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company”) is pleased to announce that Professor Dr. (h.c.) Marilyn Huestis has been appointed as a Scientific Advisor to Cannabix Technologies Inc. Dr. Huestis is one of the world’s foremost experts on the effects of marijuana use on driving impairment. Dr. Huestis will work with Cannabix in the development of its marijuana breathalyzer and provide key guidance on testing and regulatory approvals.
Dr. Huestis is a sought after international speaker, scholar and scientist. For the last 23 years, Dr. Huestis was a tenured Senior Investigator and Chief of Chemistry and Drug Metabolism at National Institute for Drug Abuse (NIDA’s) Intramural Research Program (IRP) in Baltimore, Maryland and a Professor at the University of Maryland School of Medicine. Dr. Huestis is internationally known and respected for her work on cannabinoid agonists and antagonists, in utero drug exposure, and novel psychoactive compounds. She retired from NIDA in early 2016.
As a world-renowned expert on human drug testing, Dr. Huestis currently serves on the new National Commission on Forensic Science; the Organization of Scientific Area Committee on Toxicology; the World Anti-doping Agency’s Prohibited List Committee; the Transportation Research Board Committee on Alcohol and Other Drugs; and the National Safety Council’s Alcohol, Drugs and Impairment Division Executive Board.
Dr. Huestis received her Bachelor’s degree (cum laude) in Biochemistry from Mount Holyoke College, a Master's in Clinical Chemistry with honors from the University of New Mexico, and a Ph.D. in Toxicology with honors from the University of Maryland School of Medicine. In 2010, she was selected for a Doctor Honoris causa in Medicine and Surgery from the Faculty of Medicine, University of Helsinki, Finland. Dr. Huestis has more than 410 peer-reviewed manuscripts in high impact journals in the field, serves on 6 editorial boards, and served as primary mentor to 13 toxicology doctoral students; and a member of the committee of 7 more from around the world.
Dr. Raj Attariwala, Cannabix’s Chief Scientific Officer, states, “Cannabix is excited to be able to work with Dr. Huestis as her knowledge of the effects of marijuana use on driving impairment are second to none. Her work has been instrumental in the development of policy and understanding in this complex area of study. Her leadership at NIDA and vast network will be invaluable to Cannabix.”
We seek Safe Harbor.
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.